Alectos Therapeutics

    OverviewSuggest Edit

    Alectos Therapeutics is a pharmaceutical company dedicated to the discovery and development of small-molecule therapeutics for the treatment of Alzheimer’s and Parkinson’s diseases and related tauopathies. It focuses on preclinical drug development, target validation, hit-to-lead optimization, and IND (investigational new drug)-enabling studies. 
    TypePrivate
    Founded2007
    Websitealectos.com

    Latest Updates

    Employees (est.) (Jul 2020)14(+8%)
    Cybersecurity ratingAMore

    Key People/Management at Alectos Therapeutics

    Ernest McEachern

    Ernest McEachern

    President & CEO
    David Vocadlo

    David Vocadlo

    CSO
    Yuanxi Zhou

    Yuanxi Zhou

    Director of Medicinal Chemistry
    Show more

    Alectos Therapeutics Financials and Metrics

    Summary Metrics

    Founding Date

    2007

    Alectos Therapeutics Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    92/100

    SecurityScorecard logo

    Alectos Therapeutics Online and Social Media Presence

    Embed Graph

    Alectos Therapeutics Frequently Asked Questions

    • When was Alectos Therapeutics founded?

      Alectos Therapeutics was founded in 2007.

    • Who are Alectos Therapeutics key executives?

      Alectos Therapeutics's key executives are Ernest McEachern, David Vocadlo and Yuanxi Zhou.

    • How many employees does Alectos Therapeutics have?

      Alectos Therapeutics has 14 employees.

    • Who are Alectos Therapeutics competitors?

      Competitors of Alectos Therapeutics include Genprex, GeoVax and Phio Pharmaceuticals.